



TITLE:

Thromboxane A2 is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions

AUTHOR(S):

Andoh, Tsugunobu; Yamamoto, Ai; Haza, Satomi; Yuhki, Koh-ichi; Ushikubi, Fumitaka; Narumiya, Shu; Kuraishi, Yasushi

CITATION:

Andoh, Tsugunobu ...[et al]. Thromboxane A2 is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions. *Acta Dermato Venereologica* 2016, 96(7): 899-904

ISSUE DATE:

2016

URL:

<http://hdl.handle.net/2433/226283>

RIGHT:

© 2016 The Authors. All articles are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

INVESTIGATIVE REPORT

Thromboxane A₂ is Involved in Itch-associated Responses in Mice with Atopic Dermatitis-like Skin Lesions

Tsugunobu ANDOH¹, Ai YAMAMOTO¹, Satomi HAZA¹, Koh-ichi YUHKI², Fumitaka USHIKUBI², Shu NARUMIYA³ and Yasushi KURAISHI⁴

¹Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, ²Department of Pharmacology, Asahikawa Medical University, Asahikawa, ³Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, and ⁴Research Administration Division, Tokyo Medical and Dental University, Tokyo, Japan

To investigate the mechanisms underlying itching in atopic dermatitis, we examined whether thromboxane (TX) A₂, an arachidonic acid metabolite, is involved in spontaneous scratching, an itch-related response, in NC mice with atopic dermatitis-like skin lesions. The TXA₂ receptor (TP) antagonist ONO-3708 inhibited the spontaneous scratching. The mRNA expression of TX synthase (TXSyn) distributed mainly in epidermis and the concentration of TXB₂, a metabolite of TXA₂, were increased in lesional skin. Scratching caused by the PAR2 agonist SLIGRL-NH₂ was suppressed by ONO-3708. SLIGRL-NH₂-induced scratching decreased approximately 75% in TP-deficient mice, compared to wild-type mice. In primary cultures of mouse keratinocytes, SLIGRL-NH₂ induced the production of TXA₂, as evidenced by the increased TXB₂, which was inhibited by the TXSyn inhibitor sodium ozagrel and a PAR2-neutralizing antibody. Taken together, these results suggest that epidermal TXA₂, which may be produced via PAR2 activation, is involved in itching in atopic dermatitis. **Key words:** *itch; thromboxane A₂; TP receptor; thromboxane synthase; atopic dermatitis; proteinase-activated receptor 2.*

Accepted Apr 6, 2016; Epub ahead of print Apr 12, 2016

Acta Derm Venereol 2016; 96: 899–904.

Tsugunobu Andoh, Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-1094, Japan. E-mail: andoh@pha.u-toyama.ac.jp

Atopic dermatitis (AD) is a severe, chronic inflammatory skin disease and itching constitutes its major diagnostic criterion (1–3). In AD patients, scratching induced by the itch sensation aggravates dermatitis and increases the frequency of itching (4). Therefore, itch control is very important for improving quality of life and treating AD. Although H₁ histamine receptor antagonists often serve as the drug of first choice for treating itching, AD-derived itching responds poorly to these drugs (5), suggesting that histamine is not essential for AD itching. Therefore, a comprehensive understanding of the mechanisms and mediators underlying AD itching is limited.

Glucocorticoids attenuate itching in chronic skin diseases including AD (6–8). The mechanisms underlying the pharmacological action of glucocorticoids including the inhibition of phospholipase A₂ (9) and the regulation of the expression of cyclooxygenase (COX)-2, but not COX-1 (10), have been elucidated. These findings suggest that arachidonic acid metabolites, which are regulated by glucocorticoids, are involved in the itch sensation.

Thromboxane (TX) A₂ is an arachidonic acid metabolite produced by catalysis with COX and TX synthase (TXSyn) and is altered spontaneously to form inactive TXB₂. Additionally, TXA₂ exerts its pharmacological activity (e.g., platelet aggregation) via the thromboxane TXA₂ receptor (TP), a G-protein coupled receptor (11) also involved in allergic skin inflammation (12). In patients with pruritic diseases, the serum concentration of TXB₂, a metabolite (and therefore an indicator) of TXA₂, is increased (13–16). Moreover, intradermal injection of TXA₂ elicits scratching, an itch-associated response, in mice (17). These results suggest that TXA₂ plays an important role in the itching sensation that accompanies several pruritic skin diseases. However, it remains unclear whether TXA₂ is involved in AD-associated itching.

NC mice that are maintained for a long time in a conventional environment develop chronic dermatitis, hyperplasia, dry skin, increased serum IgE levels, mast cells in the skin and spontaneous scratching, an itch-related behavior (18, 19); these features are similar to those of AD patients (1–3). In this study, we investigated whether TXA₂ is involved in spontaneous itching in NC mice with AD-like chronic dermatitis.

MATERIALS AND METHODS

Animals

Male NC/Nga mice (14–21 weeks old), purchased from Japan SLC (Hamamatsu, Japan), were used in this study. The mice were bred in a specific pathogen-free environment at the Division of Animal Resource and Development, Life Science Research Center, University of Toyama, and in a conventional environment in the experimental animal room in the Department of Applied Pharmacology, University of Toyama. All mice, except for the healthy controls, were kept together with mite-infected mice with chronic dermatitis for 2 weeks at 4–5 weeks of age in a conventional environment in the experimental animal

room (19). These mice exhibited severe dermatitis after one and two months. In one series of experiments, TP receptor-deficient mice (TP-R^{-/-}) mice with a C57BL/6 genetic background and wild-type mice were used at 11 weeks of age (20). The mice were housed in a room with controlled temperature (21–23°C), humidity (45–65%), and light cycle (lights on from 08:00 to 20:00 h). Food and water were freely available. All animal experiment procedures were approved by the Committee for Animal Experiments at the University of Toyama and Asahikawa Medical University and were conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, 2006).

Agents (see Appendix S1¹)

Primary cultures of mouse keratinocytes (see Appendix S1¹)

Behavioral experiments (see Appendix S1¹)

Real-time PCR (see Appendix S1¹)

Reverse transcription and PCR (see Appendix S1¹)

Enzyme immunoassay for TXB₂

Animals were anesthetized with sodium pentobarbital (80 mg/kg) and transcardially perfused with phosphate-buffered saline (PBS). The skin was isolated using an 8-mm-diameter punch, immediately shredded with scissors, and added to 1 ml of ice-chilled ethanol containing 10 μ M indomethacin and 10 μ M zileuton to inhibit cyclooxygenase and 5-lipoxygenase, respectively. Following homogenization, each sample was centrifuged at 600 \times g at 4°C for 10 min. The supernatant (0.8 ml) was mixed with 5 ml of distilled water (pH 3.0) and applied to a C₁₈ Sep-Pak cartridge (Waters, Milford, MA, USA) equilibrated with methanol. The cartridges were washed with hexane followed by distilled water and the lipids were then eluted with methyl formate. The eluted fraction was then evaporated and the resulting residue was suspended in an enzyme immunoassay buffer (Cayman Chemical, Ann Arbor, MI, USA) for the assay of TXB₂. The amount of TXB₂ was determined using an enzyme immunoassay kit (Cayman Chemical). In the case of cultured keratinocytes, the culture medium was changed to mouse keratinocyte growth medium (CnT-Prime basal medium; CELLnTEC Advanced Cell Systems AG), as the assay medium. Samples for the assay of TBX₂ were obtained from the supernatant 5 min post SLIGRL-NH₂ administration. Following collection of culture medium, the cultured keratinocytes were treated with 1% Triton X-100 to solubilize the cell proteins. Total protein concentration was determined using a Bio-Rad Protein Assay Kit (Hercules, CA, USA) and TXB₂ concentration was measured using an enzyme immunoassay kit (Cayman Chemical). The concentration of TXB₂ in keratinocytes was normalized to a skin section (8-mm diameter) and total protein concentration, respectively.

Immunostaining

Under anesthesia with sodium pentobarbital (80 mg/kg, intraperitoneal), the animals were transcardially perfused with PBS following by with 4% paraformaldehyde (PFA). The skin of the rostral back was isolated, post-fixed with 4% PFA and then immersed in 30% sucrose solution for 2 days. The tissue was then embedded in Tissue-Tek1 O.C.T. Compound (Sakura Finetek Co., Ltd., Tokyo, Japan) and the frozen samples were sectioned at 16 μ m with a cryostat (Leica, Wetzlar, Germany).

The sections were washed with PBS and then treated with Protein Block® (DAKO Co., Hamburg, Germany) followed by 0.3% Triton X-100 in PBS. The sections were treated with anti-TXSyn antibody (Cayman Chemical) at 4°C overnight. For some experiments, sections were treated with the antibody (Cayman Chemical) pre-incubated with its specific antigen prior to staining. Subsequent to washing with PBS, the preparations were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG (Life Technologies, Carlsbad, CA, USA) for 1 h at room temperature. Fluorescence signals were observed using a fluorescence microscope (BX-61/DP70, Olympus, Tokyo, Japan). Fluorescent intensity was analyzed with NIH Image software (National Institute of Health, Bethesda, MD, USA).

Statistical analysis

Data are presented as mean \pm S.E.M. The statistical significance of differences between group means was analyzed using the Student's *t*-test (two groups) or one-way analysis of variance (ANOVA) followed by a *post-hoc* Holm–Šidák test (3 or more groups). A *p*-value < 0.05 was considered statistically significant.

RESULTS

Spontaneous scratching in NC mice with chronic dermatitis

Fig. 1A shows the number of spontaneous bouts of hind paw scratching towards any region of the body in individual healthy and chronic dermatitis NC mice. Although the healthy mice did not exhibit spontaneous scratching, most age-matched chronic dermatitis mice exhibited apparent spontaneous scratching. In the following experiments, we used healthy NC mice that were given intradermal injections of SLIGRL-NH₂. In other experiments, healthy and chronic dermatitis NC mice were compared.




Fig. 1. (A) Comparison of spontaneous scratching between healthy and dermatitis mice. Spontaneous hind paw scratching towards any region of the body was counted for 1 h at 21 weeks of age. Healthy mice were kept under specific pathogen-free (SPF) conditions and dermatitis mice were transferred to a conventional environment (CNV) at 4–5 weeks of age. Open circles represent the values for individual animals; the horizontal bars represent the means ($n = 10$ each). * $p < 0.05$ (Student's *t*-test). (B) Effects of ONO-3708 on spontaneous scratching in NC mice with chronic dermatitis. Either ONO-3708 or the vehicle (VH) was administered orally 1 h prior to observation. The broken line represents the mean number of scratch bouts in healthy mice. Values represent the mean and S.E.M. ($n = 16$). * $p < 0.05$, as compared with VH-treated mice (Holm–Šidák test).

¹<http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2437>

Effects of TP antagonist on spontaneous scratching in NC mice with chronic dermatitis

The TP receptor antagonist ONO-3708 (30 or 100 mg/kg) significantly inhibited spontaneous scratching in NC mice with chronic dermatitis, compared with the vehicle-treated group (Fig. 1B).

Effects of the TP receptor antagonist and TP receptor-deficiency on SLIGRL-NH₂-induced scratching

PAR2 is involved in spontaneous scratching in NC mice with chronic dermatitis (24). Intradermal injection of SLIGRL-NH₂ (100 nmol/site), a PAR2 agonist peptide, elicited scratching in healthy NC mice (Fig. 2). ONO-3708 (30 and 100 mg/kg) significantly inhibited scratching induced by SLIGRL-NH₂ compared with the vehicle-treated group (Fig. 2A). While SLIGRL-NH₂ (100 nmol/site) induced scratching in wild-type mice, the scratching was decreased by approximately 75% in TP-deficient mice, compared with that in wild-type mice (Fig. 2B). The mRNA expressions of TP receptor, TXSyn and PAR2 in the skin and DRG in wild-type and TP-deficient mice are shown in Fig. S1¹.

Expression of TXSyn mRNA and TXB₂ concentration in NC mouse skin

The expression of TXSyn mRNA (Fig. 3A) and TXB₂, a stable degradation product of TXA₂ (Fig. 3B), were significantly higher in the lesional skin of NC mice with chronic dermatitis than in the skin of healthy NC mice.

Distribution of TXSyn in the skin of NC mice

In contrast to healthy skin, the lesional skin of NC mice with chronic dermatitis exhibited epidermal hyperplasia (Fig. 4). Immunohistochemical staining and fluorescent




Fig. 2. Effects of the thromboxane (TX) A_2 receptor (TP) antagonist ONO-3708 on SLIGRL-NH₂-induced scratching. (A) SLIGRL-NH₂ (100 nmol/site) was injected intradermally into the rostral back of healthy NC mice. ONO-3708 or the vehicle (VH) was administered orally 1 h prior to SLIGRL-NH₂ injection. The broken line represents the mean number of scratch bouts in the saline-injected group. Values represent the mean and S.E.M. ($n=8$). * $p<0.05$, as compared with VH-treated group (Holm-Šidák test). (B) SLIGRL-NH₂ (100 nmol/site) or saline was injected intradermally into the rostral back of TP-deficient (TP-R^{-/-}) or the wild-type (WT) mice. Values represent the mean and S.E.M. ($n=6-8$). * $p<0.05$, as compared with saline-injected group (WT), # $p<0.05$, as compared with SLIGRL-injected group (WT) (Holm-Šidák test).




Fig. 3. (A) Expression level of TXSyn mRNA in the skin of healthy (lesional) or dermatitis mice (NC). The mRNA levels were determined in 8-mm diameter punch skin of the rostral back by real-time PCR. The mRNA levels were normalized to the level of glyceraldehyde-3-phosphate dehydrogenase in each sample and then to the mean level observed in the healthy control mice. Values represent the means and S.E.M. ($n=9$). * $p<0.05$ (Student's t -test). (B) TXB₂ concentration in the skin of healthy or dermatitis (lesional) mice. The TXB₂ concentration in the rostral back skin of healthy or dermatitis mice was measured by an enzyme immunoassay. Values represent the mean and S.E.M. ($n=10$). * $p<0.05$ (Student's t -test).




Fig. 4. Thromboxane synthase (TXSyn). Representative images of TXSyn (green) immunostaining in the skin of healthy (Top) and dermatitis (Middle) NC mice. Skin samples of dermatitis NC mice were also immunostained with the pre-absorbed TXSyn antibody (Bottom). Dotted lines indicate the boundary between the dermis (D) and epidermis (ED). The values in parenthesis indicate the fluorescence intensity ratio in the ED and D (ED/D); scale bar = 100 μ m.

intensity analysis in the epidermis and dermis revealed that TXSyn is predominantly expressed in epidermal keratinocytes (Fig. 4). Staining was eliminated when pre-absorbed antibody was used (Fig. 4 bottom).

The production of TXA₂ induced by SLIGRL-NH₂ in primary cultures of mouse keratinocytes

Both TXSyn and PAR2 mRNA were expressed in primary cultures of mouse keratinocytes (Fig. 5A).




Fig. 5. The production of thromboxane (TX)A₂ induced by SLIGRL-NH₂ in primary cultures of mouse keratinocytes. (A) The expression levels of TX synthase (TXSyn) and proteinase-activated receptor 2 (PAR2) mRNA were determined using reverse transcription (RT)-PCR. Typical examples of the bands of RT-PCR products for TXSyn, PAR2 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA are seen in the gel. (B) Effects of the TXSyn inhibitor sodium ozagrel on SLIGRL-NH₂-induced TXA₂ production. Sodium ozagrel was applied 5 min prior to the application of SLIGRL-NH₂. Since TXA₂ is altered spontaneously to form inactive TXB₂, the TXB₂ content in the assay medium was measured using an enzyme immunoassay. Values represent the mean and S.E.M. (*n* = 6). **p* < 0.05, as compared with assay medium alone, #*p* < 0.05, as compared with SLIGRL-NH₂ (200 μM) alone (Holm-Šidák test). (C) Effect of PAR2-neutralized antibody on SLIGRL-NH₂-induced TXA₂ production. All cultures were exposed to Non-specific IgG (nlgG) (1:500) or PAR2-neutralized antibody (PAR2ab, 1:500) 10 min prior to the application of SLIGRL-NH₂ (200 μM). Values represent the means and S.E.M. (*n* = 6). **p* < 0.05, as compared with nlgG alone, #*p* < 0.05, as compared with nlgG+SLIGRL-NH₂ (Holm-Šidák test).

SLIGRL-NH₂ (20–200 μM) induced TXA₂ production, as determined by an increase in TXB₂ concentration in primary cultures of mouse keratinocytes (Fig. 5B). SLIGRL-NH₂-induced TXA₂ production was significantly inhibited by the TXSyn inhibitor sodium ozagrel (1–10 μM) (Fig. 5B). In addition, the PAR2-neutralized antibody (Fig. S2¹) also attenuated the TXA₂ production inhibited by SLIGRL-NH₂ (Fig. 5C).

DISCUSSION

Responses to pruritogens differ among mouse species (25). An intradermal injection of histamine (10–1,000 nmol/site) did not induce scratching in healthy NC mice (Fig. S3¹), suggesting that NC mice respond minimally to histamine. Thus, pruritogens other than histamine are involved in the observed spontaneous scratching in NC mice with chronic dermatitis. The results of the present study show that the TP receptor antagonist ONO-3708 inhibits spontaneous scratching in NC mice with chronic dermatitis. In healthy NC mice, an intradermal injection of the TXA₂ analogue U-46619 (1–100 nmol/site) elicited dose-dependent scratching (Fig. S3¹). Additionally, U-46619-induced scratching was inhibited by ONO-3708 (Fig. S4¹). ONO-3708 inhibits receptor binding of U-46619 but not TXB₂, leukotriene D₄, or prostaglandin D₂ and E₁ (21, 22), suggesting that the action of U-46619 is mediated via the TP receptor. Both TXSyn mRNA expression and TXA₂ production, as gauged by TXB₂ concentration, were increased in the skin of NC mice with chronic dermatitis. These results suggest that TXA₂ and its receptor are involved in spontaneous itching in NC mice with chronic dermatitis.

TXSyn is a key enzyme involved in the synthesis of TXA₂ from prostaglandin H₂, a metabolite of arachidonic acid (26). TXSyn was predominately expressed in epidermal keratinocytes in the skin of both healthy and dermatitis NC mice. Previously, we have also shown that keratinocytes express TXSyn in ICR mice, which are untreated healthy mice (17). Mast cells in the skin also express TXSyn and produce TXA₂ via immunological stimulation (27). However, the TXA₂ content is much lower than the contents of other arachidonic acids metabolites, such as prostaglandin D₂ and leukotriene C₄ (27). In addition, no immunoreactivity against TXSyn was observed in the dermis, where the mast cells are distributed, of either healthy or dermatitis NC mice. Therefore, these results do not support the involvement of mast cell TXA₂ in itching in NC mice with chronic dermatitis. However, it is still possible that mast cell-derived TXA₂ is involved in itching associated with dermatitis. Taken together, these findings indicate that epidermal keratinocytes constitute the main source of TXA₂ production in lesional skin.

In the skin of NC mice with chronic dermatitis, expression of TXSyn mRNA was increased. The AP-1

family of transcription factors plays an important role in the promotor activity for TXSyn (28). Increased immunoreactivity to AP-1-related transcription factors (e.g., Jun D, c-Fos, Fos B, Fra-1, and Fra-2) has been observed in the epidermis (29) of AD patients compared to that of healthy subjects. Jun D and c-Fos, in particular, exhibit strong cytoplasmic positivity in the epidermis of AD patients (29). Thus, the increase in AP-1 expression may be related to the elevated TXSyn expression in atopic dermatitis-like skin lesions.

The mechanisms underlying TXA₂ production in lesional skin are not completely understood. Previously, we have demonstrated that serine proteinase and PAR2 are involved in itch-related responses in NC mice with chronic dermatitis (24). In this study, the PAR2 agonist peptide SLIGRL-NH₂-induced itch-related responses were inhibited by a TP receptor antagonist in healthy NC mice and were decreased in TP receptor-deficient mice, suggesting that TXA₂ is involved in PAR2-related responses. PAR2 is predominately expressed in epidermal keratinocytes (24). In primary cultures of NC mouse keratinocytes, the application of a PAR2 agonist peptide induced the production of TXA₂, and this response was inhibited by the TX inhibitor and the PAR2-neutralizing antibody. Thus, PAR2 activation may be involved in the production of TXA₂ in keratinocytes. PAR2 is activated by trypsin-like serine proteases (e.g., tryptase and kallikrein 5) and a synthetic PAR2-tethered ligand known as PAR2 agonist peptide (30–32). In NC mice with chronic dermatitis, tryptase from mast cells (24) and kallikrein 5 from keratinocytes (33) are involved in itching behavior, suggesting that these serine-proteases play an important role in the production of TXA₂. There are at least two possible pathways by which keratinocytes produce TXA₂ following PAR2 stimulation. PAR2 is a G-protein-coupled receptor (30) and its activation increases the level of free intracellular Ca²⁺ ions (30, 34, 35). Thus, the activation of phospholipase A₂ via increased free intracellular Ca²⁺ ions (36) may promote TXA₂ production. Production may also occur via Rho kinase-mediated phospholipase A₂ activation (37); the activation of PAR2 stimulates Rho kinase activity (38). In addition to the increase in TXSyn expression, these two pathways may contribute to the production of TXA₂ in the lesional skin of NC mice with chronic dermatitis.

In the skin, TP receptors are predominantly expressed in keratinocytes and primary afferent neurons (17) (Fig. S3¹). In addition, TP receptors are expressed in small-size neurons in the dorsal root ganglion (17); these have chiefly unmyelinated C-fibers (39, 40), which play an important role in itch signaling (41, 42). The application of the TXA₂ analogue U-46619 increases the concentration of free intracellular Ca²⁺ ions, which is inhibited by the TP receptor antagonist, in primary cultures of dorsal root ganglion neurons (17). The action of U-46619 is also inhibited by L-type calcium channel blockers, sugges-

ting that the activation of TP receptors elicits membrane depolarization (43). These observations suggest that TXA₂ acts on primary afferent neurons or through both autocrine and paracrine mechanisms in keratinocytes. Additionally, intra-epidermal neurites increase in the skin of NC mice with chronic dermatitis (44) and patients with atopic dermatitis (45, 46). These findings also support the hypothesis that TXA₂ released from keratinocytes acts directly on primary afferent neurons.

In conclusion, we demonstrated that TXA₂ produced by epidermal keratinocytes is involved in spontaneous itch-related behavior in NC mice with AD-like skin lesions. Moreover, we found that the serine protease-PAR2 system partially contributes to the production of TXA₂. PAR2, TXSyn and TP receptor may constitute potential new targets for the development of antipruritic drugs for AD.

ACKNOWLEDGMENTS

We are very grateful to Ono Pharmaceutical Co. Ltd. for providing the gift of ONO-3708. This study was supported in part by Japan Agency for Medical Research and Development.

The authors declare no conflicts of interest.

REFERENCES

1. Hanifin JM. Atopic dermatitis. *J Am Acad Dermatol* 1982; 6: 1–13.
2. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *J Allergy Clin Immunol* 2006; 118: 152–169.
3. Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JH. Atopic eczema or atopiform dermatitis. *Exp Dermatol* 2010; 19: 325–331.
4. Wahlgren CF. Itch and atopic dermatitis: an overview. *J Dermatol* 1999; 26: 770–779.
5. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. *Acta Derm Venereol* 1991; Suppl 165: 1–53.
6. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. *Br J Dermatol* 1975; 93: 303–312.
7. Lassus A. Clinical comparison of alclometasone dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children. *J Int Med Res* 1983; 11: 315–319.
8. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol* 2008; 158: 801–807.
9. Piltch A, Sun L, Fava RA, Hayashi J. Lipocortin-independent effect of dexamethasone on phospholipase activity in a thymic epithelial cell line. *Biochem J* 1989; 261: 395–400.
10. Zhang MZ, Harris RC, McKanna JA. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. *Proc Natl Acad Sci U S A* 1999; 96: 15280–15285.

11. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. *Physiol Rev* 1999; 79: 1193–1226.
12. Nagai H. Prostaglandin as a target molecule for pharmacotherapy of allergic inflammatory diseases. *Allergol Int* 2008; 57: 187–196.
13. Marks JG Jr, Trautlein JJ, Zwillich CW, Demers LM. Contact urticaria and airway obstruction from carbonless copy paper. *JAMA* 1984; 252: 1038–1040.
14. Myśliwiec M, Bodzenta A, Rydzewski A, Soszka J. Plasma thromboxane B₂ in haemodialysed patients. *Folia Haematol Int Mag Klin Morphol Blutforsch* 1985; 112: 442–446.
15. Grekas D, Alivannis P, Karamouzis M, Pырpasopoulos M. Piracetam as a potent inhibitor of plasma thromboxane B₂ during hemodialysis. *Nephron* 1989; 52: 372–373.
16. Veale DJ, Torley HI, Richards IM, O'Dowd A, Fitzsimons C, Belch JJ, Sturrock RD. A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. *Br J Rheumatol* 1994; 33: 954–958.
17. Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H, Narumiya S, Kuraishi Y. Thromboxane A₂ induces itch-associated responses through TP receptors in the skin in mice. *J Invest Dermatol* 2007; 127: 2042–2047.
18. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. *Int Immunol* 1997; 9: 461–466.
19. Yamaguchi T, Maekawa T, Nishikawa Y, Nojima H, Kaneko M, Kawakita T, et al. Characterization of itch-associated responses of NC mice with mite-induced chronic dermatitis. *J Dermatol Sci* 2001; 25: 20–28.
20. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, et al. Roles of prostaglandin I₂ and thromboxane A₂ in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. *Circulation* 2001; 104: 2210–2215.
21. Narumiya S, Okuma M, Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. *Br J Pharmacol* 1986; 88: 323–331.
22. Nagai H, Tsuji F, Inagaki N, Kitagaki K, Fukutomi O, Koda A, Daikoku M. The effect of ONO-3708, a novel TxA₂ receptor antagonist, on U-46619-induced contraction of guinea pig and human tracheal strips in vitro and on bronchoconstriction in guinea pigs in vivo. *Prostaglandins* 1991; 41: 375–382.
23. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratching behavior induced by pruritogenic but not algescogenic agents in mice. *Eur J Pharmacol* 1995; 275: 229–233.
24. Tsujii K, Andoh T, Ui H, Lee JB, Kuraishi Y. Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. *J Pharmacol Sci* 2009; 109: 388–395.
25. Inagaki N, Nagao M, Igeta K, Kawasaki H, Kim JF, Nagai H. Scratching behavior in various strains of mice. *Skin Pharmacol Appl Skin Physiol* 2001; 14: 87–96.
26. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A₂ from prostaglandin endoperoxides. *Nature* 1976; 261: 558–560.
27. Mita H, Ishii T, Akiyama K. Generation of thromboxane A₂ from highly purified human sinus mast cells after immunological stimulation. *Prostaglandins Leukot Essent Fatty Acids* 1999; 60: 175–180.
28. Zhang L, Xiao H, Schultz RA, Shen RF. Genomic organization, chromosomal localization, and expression of the murine thromboxane synthase gene. *Genomics* 1997; 45: 519–528.
29. Pastore S, Giustizieri ML, Mascia F, Giannetti A, Kaushansky K, Girolomoni G. Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor. *J Invest Dermatol* 2000; 115: 1134–1143.
30. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. *Pharmacol Rev* 2001; 53: 245–282.
31. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Blaber M, et al. Kallikrein-mediated cell signaling: targeting proteinase-activated receptors (PARs). *Biol Chem* 2006; 387: 817–824.
32. Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, Egelrud T. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. *J Invest Dermatol* 2008; 128: 18–25.
33. Andoh T, Tsujii K, Kuraishi Y. Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis. *Exp Dermatol* 2015; 24: 978–980.
34. Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, et al. Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. *Proc Natl Acad Sci USA* 1995; 92: 9151–9155.
35. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. *Biochem J* 1996; 314: 1009–1016.
36. Clark JD, Milona N, Knopf JL. Purification of a 110-kilodalton cytosolic phospholipase A₂ from the human monocytic cell line U937. *Proc Natl Acad Sci U S A* 1990; 87: 7708–7712.
37. Chen LY, Woszczek G, Nagineni S, Logun C, Shelhamer JH. Cytosolic phospholipase A₂α activation induced by S1P is mediated by the S1P₃ receptor in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2008; 295: L326–L335.
38. Sriwai W, Mahavadi S, Al-Shboul O, Grider JR, Murthy KS. Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: feedback inhibition of RhoA by cAMP-independent PKA. *PLoS One* 2013; 8: e66743.
39. Harper AA, Lawson SN. Conduction velocity is related to morphological cell type in rat dorsal root ganglion neurons. *J Physiol* 1985; 359: 31–46.
40. Lee KH, Chung K, Chung JM, Coggeshall RE. Correlation of cell body size, axon size, and signal conduction velocity for individually labelled dorsal root ganglion cells in the cat. *J Comp Neurol* 1986; 243: 335–346.
41. Handwerker HO, Forster C, Kirchhoff C. Discharge patterns of human C-fibers induced by itching and burning stimuli. *J Neurophysiol* 1991; 66: 307–315.
42. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specific C-receptors for itch in human skin. *J Neurosci* 1997; 17: 8003–8008.
43. Arshad M, Vijay V, Floyd BC, Marks B, Sarabu MR, Wolin MS, Gupte SA. Thromboxane receptor stimulation suppresses guanylate cyclase-mediated relaxation of radial arteries. *Ann Thorac Surg* 2006; 81: 2147–2154.
44. Tominaga M, Ozawa S, Ogawa H, Takamori K. A hypothetical mechanism of intraepidermal neurite formation in NC/Nga mice with atopic dermatitis. *J Dermatol Sci* 2007; 46: 199–210.
45. Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M. Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. *Arch Dermatol Res* 1997; 289: 125–131.
46. Tominaga M, Ogawa H, Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. *Br J Dermatol* 2008; 158: 842–844.